- Policy
- Moderna apologized to the gov for the disruption in supply
- by Kim, Jung-Ju Aug 18, 2021 05:51am
- Kang Do-tae, the second vice minister of welfare, and other delegations visited the U.S. headquarters for an interview. The government visited the U.S. headquarters of Moderna that supplies the vaccine worldwide to protest against the supply disruption and ask for quick measures. The delegation, composed of Kang Do-tae, the second Vice
- Company
- Will GSK-SK Bioscience distribute flu vaccines?
- by Aug 18, 2021 05:51am
- It is not clear whether the distribution contract for Fluarix Tetra, a seasonal flu vaccine under way between SK Bioscience and GSK, will be distributed ahead of the inoculation season. According to the pharmaceutical industry on the 13th, SK Bioscience is likely not to market GSK's Fluarix Tetra this year. Sanogi's flu vaccine, Vaxigrip,
- Company
- Medication imports in July are the largest ever
- by Kim, Jin-Gu Aug 17, 2021 05:53am
- Pharmaceutical exports of &8361;700 billion have remained strong since last year. In July, domestic drug imports reached &8361;1 trillion, the highest record ever. It is analyzed that it is a phenomenon caused by the full-fledged import of vaccines from Pfizer and Moderna. ◆Monthly import amount is close to &8361;1 trillion, up 25%
- Company
- Insulin·GLP-1 combo Xultophy lands in ‘Big 5’ hospitals
- by Eo, Yun-Ho Aug 17, 2021 05:52am
- The insulin and GLP-1 receptor agonist combination drug ‘Xultophy’ can now be prescribed in general hospitals. According to industry sources, Xultophy FlexTouch inj., a fixed-ration combination of Novo Nordisk Korea’s insulin Tresiba (insulin degludec)’ and the GLP receptor antagonist ‘Victoza (liraglutide injection),' has passed the
- Policy
- Opdivo's RSA renewed… benefit extended for use with Yervoy
- by Lee, Hye-Kyung Aug 17, 2021 05:52am
- ‘Opidivo inj. (nivolumab),’ the first cancer immunotherapy approved in Korea has successfully extended its contract ahead termination of its risk-sharing agreement (RSA) term. In addition to Opdivo, the breast cancer treatment ‘Kisqali (ribosiclib) was also included in the list of drugs that completed negotiations with the National Health
- Policy
- SK Chemical will sell Zemplar
- by Lee, Tak-Sun Aug 17, 2021 05:52am
- The original Zemplar (Paricalcitol) will be sold by SK Chemical in Korea. It is imported and supplied by AbbVie Korea, and SK Chemical has been in charge of distribution, sales and marketing in Korea since July. SK Chemical is expected to compete fiercely with generic companies. According to industries on the 12th, SK Chemical has been di
- Policy
- GBP510 has been approved for Phase 3, the 1st time in Korea
- by Lee, Tak-Sun Aug 17, 2021 05:52am
- Domestic developed COVID-19 vaccine has entered the final stage of commercialization. A candidate for the COVID-19 vaccine developed by SK Bioscience will conduct phase 3 clinical trial. The MFDS announced on Tuesday that it approved phase 3 clinical trial plan for the first domestic COVID-19 vaccine after thoroughly verifying its safety and
- Company
- Reimb. to be expanded for PARP inhibitor Lynparza and Zejula
- by Eo, Yun-Ho Aug 13, 2021 05:58am
- The PARP inhibitors ‘Lynparza’ and ‘Zejula’ both crossed the last hurdle in extending their insurance benefits. According to industry sources, AstraZeneca Korea and Takeda Pharmaceuticals Korea have both completed drug pricing negotiations with the National Health Insurance Service (NHIS) to expand their PARP (poly ADP ribose polymera
- Opinion
- [Reporter's view] Unstable supply of imported vaccines
- by Lee, Tak-Sun Aug 13, 2021 05:58am
- Moderna's unstable supply and demand disrupted the vaccination. Moderna's vaccine was originally scheduled to come in 8.5 million doz in August, but Moderna informed that it would supply less than half of the vaccine due to laboratory problems related to production. As a result, not only Moderna but also the first and second vaccinations of t
- Company
- Alvogen is targeting patents for Roche's Avastin
- by Kim, Jin-Gu Aug 13, 2021 05:58am
- Alvogen Korea has started patenting Roche's blockbuster anti-cancer drug Avastin (Bevacizumab). Two types of Avastin biosimilar are already licensed in Korea. According to the pharmaceutical industry on the 12th, Alvogen Korea recently filed an invalid trial on Roche's two patents of Avastin. Roche is registering a total of four patent
